Zogenix Competitors

Johnson & Johnson (NYSE:JNJ) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Earnings & Valuation

This table compares Johnson & Johnson and Zogenix's top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Johnson & Johnson and Zogenix, as provided by MarketBeat.com.

Johnson & Johnson currently has a consensus target price of $182.6154, suggesting a potential upside of 12.56%. Zogenix has a consensus target price of $58.25, suggesting a potential upside of 206.58%. Given Zogenix's stronger consensus rating and higher probable upside, analysts clearly believe Zogenix is more favorable than Johnson & Johnson.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 96.6% of Zogenix shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 3.5% of Zogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Johnson & Johnson and Zogenix's net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Zogenix on 8 of the 14 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Risk and Volatility

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Valuation & Earnings

This table compares Pfizer and Zogenix's revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 3.5% of Zogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and Zogenix's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations for Pfizer and Zogenix, as provided by MarketBeat.com.

Pfizer currently has a consensus price target of $38.5714, indicating a potential upside of 0.00%. Zogenix has a consensus price target of $58.25, indicating a potential upside of 206.58%. Given Zogenix's stronger consensus rating and higher possible upside, analysts clearly believe Zogenix is more favorable than Pfizer.

Merck & Co., Inc. (NYSE:MRK) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 96.6% of Zogenix shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 3.5% of Zogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Zogenix's net margins, return on equity and return on assets.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Merck & Co., Inc. and Zogenix, as provided by MarketBeat.com.

Merck & Co., Inc. currently has a consensus price target of $96.2727, indicating a potential upside of 24.27%. Zogenix has a consensus price target of $58.25, indicating a potential upside of 206.58%. Given Zogenix's higher probable upside, analysts plainly believe Zogenix is more favorable than Merck & Co., Inc..

Earnings and Valuation

This table compares Merck & Co., Inc. and Zogenix's gross revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Zogenix on 9 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 3.5% of Zogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for AbbVie and Zogenix, as provided by MarketBeat.com.

AbbVie currently has a consensus price target of $115.75, suggesting a potential upside of 7.27%. Zogenix has a consensus price target of $58.25, suggesting a potential upside of 206.58%. Given Zogenix's stronger consensus rating and higher possible upside, analysts plainly believe Zogenix is more favorable than AbbVie.

Profitability

This table compares AbbVie and Zogenix's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares AbbVie and Zogenix's top-line revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Zogenix on 8 of the 14 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Earnings & Valuation

This table compares Zogenix and Eli Lilly and's gross revenue, earnings per share and valuation.

Eli Lilly and has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Zogenix and Eli Lilly and, as provided by MarketBeat.com.

Zogenix presently has a consensus price target of $58.25, suggesting a potential upside of 206.58%. Eli Lilly and has a consensus price target of $196.40, suggesting a potential upside of 3.78%. Given Zogenix's stronger consensus rating and higher possible upside, analysts clearly believe Zogenix is more favorable than Eli Lilly and.

Institutional and Insider Ownership

96.6% of Zogenix shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 3.5% of Zogenix shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Zogenix and Eli Lilly and's net margins, return on equity and return on assets.

Volatility and Risk

Zogenix has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Zogenix on 8 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zogenix (NASDAQ:ZGNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Zogenix's gross revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 3.5% of Zogenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Bristol-Myers Squibb and Zogenix, as reported by MarketBeat.

Bristol-Myers Squibb presently has a consensus target price of $74.60, indicating a potential upside of 13.96%. Zogenix has a consensus target price of $58.25, indicating a potential upside of 206.58%. Given Zogenix's higher probable upside, analysts clearly believe Zogenix is more favorable than Bristol-Myers Squibb.

Profitability

This table compares Bristol-Myers Squibb and Zogenix's net margins, return on equity and return on assets.

Summary

Bristol-Myers Squibb beats Zogenix on 9 of the 15 factors compared between the two stocks.